Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

BACKGROUND: Flavopiridol is a protein-bound, cytotoxic, cyclin dependent kinase inhibitor. A phase II trial of flavopiridol followed by ara-C and mitoxantrone with flavopiridol given by 1-h bolus for adults with newly-diagnosed, poor-risk acute myelogenous leukemia yielded 67% complete remission wit...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Karp, Judith E., Garrett-Mayer, Elizabeth, Estey, Elihu H., Rudek, Michelle A., Smith, B. Douglas, Greer, Jacqueline M., Drye, D. Michelle, Mackey, Karen, Dorcy, Kathleen Shannon, Gore, Steven D., Levis, Mark J., McDevitt, Michael A., Carraway, Hetty E., Pratz, Keith W., Gladstone, Douglas E., Showel, Margaret M., Othus, Megan, Doyle, L. Austin, Wright, John J., Pagel, John M.
Format: Artigo
Sprog:Inglês
Udgivet: Ferrata Storti Foundation 2012
Fag:
Original Articles and Brief Reports
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3487449/
https://ncbi.nlm.nih.gov/pubmed/22733022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.062539
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker